Premium
Inhaled corticosteroids during and after respiratory syncytial virus‐bronchiolitis may decrease subsequent asthma
Author(s) -
Kajosaari Merja,
Syvänen Pirkko,
Förars Merit,
JuntunenBackman Kaisu
Publication year - 2000
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1034/j.1399-3038.2000.00068.x
Subject(s) - bronchiolitis , medicine , budesonide , asthma , bronchitis , pneumovirus , respiratory system , respiratory disease , corticosteroid , pediatrics , nebulizer , anesthesia , virus , paramyxoviridae , immunology , viral disease , lung
Respiratory syncytial virus (RSV) bronchiolitis in infancy can lead to bronchial hyper‐reactivity or recurrent obstructive bronchitis. The aim of the present study was to determine whether the type of treatment has an influence on respiratory status after RSV bronchiolitis. The study involved 117 infants (mean age 2.6 months), who needed hospital treatment because of RSV bronchiolitis. The patients were divided randomly into three groups. All received the same symptomatic treatment. Group I children received symptomatic treatment only, group II children were treated for 7 days with inhaled budesonide, 500 µg three times per day, administered via a nebulizer. Group III children received nebulized budesonide, 500 µg twice per day for two months. Follow‐up consisted of out‐patient check‐ups 2 and 6 months after the infection, and telephone contact two years after the infection. Statistically significant differences were seen between the groups. In group I 37% of the children had asthma, in group II 18%, and in group III 12%. According to the present study it seems that inhaled corticosteroid treatment during and after the acute phase of infant RSV bronchiolitis may have a beneficial effect on subsequent bronchial wheezing tendency.